Evidence map›Paper›PMID 24632968›Full record

ArticlePloS one2014

Analyzing clonal variation of monoclonal antibody-producing CHO cell lines using an in silico metabolomic platform.

Atefeh Ghorbaniaghdam, Jingkui Chen, Olivier Henry, Mario Jolicoeur

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Atefeh GhorbaniaghdamCanada Research Chair in Applied Metabolic Engineering, École Polytechnique de Montréal, Montréal, Québec, Canada; Department of Chemical Engineering, École Polytechnique de Montréal, Montréal, Québec, Canada.
Jingkui ChenCanada Research Chair in Applied Metabolic Engineering, École Polytechnique de Montréal, Montréal, Québec, Canada; Department of Chemical Engineering, École Polytechnique de Montréal, Montréal, Québec, Canada.
Olivier HenryDepartment of Chemical Engineering, École Polytechnique de Montréal, Montréal, Québec, Canada.
Mario JolicoeurCanada Research Chair in Applied Metabolic Engineering, École Polytechnique de Montréal, Montréal, Québec, Canada; Department of Chemical Engineering, École Polytechnique de Montréal, Montréal, Québec, Canada.
Polytechnique Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibody producing Chinese hamster ovary (CHO) cells have been shown to undergo metabolic changes when engineered to produce high titers of recombinant proteins. In this work, we have studied the distinct metabolism of CHO cell clones harboring an efficient inducible expression system, based on the cumate gene switch, and displaying different expression levels, high and low productivities, compared to that of the parental cells from which they were derived. A kinetic model for CHO cell metabolism was further developed to include metabolic regulation. Model calibration was performed using intracellular and extracellular metabolite profiles obtained from shake flask batch cultures. Model simulations of intracellular fluxes and ratios known as biomarkers revealed significant changes correlated with clonal variation but not to the recombinant protein expression level. Metabolic flux distribution mostly differs in the reactions involving pyruvate metabolism, with an increased net flux of pyruvate into the tricarboxylic acid (TCA) cycle in the high-producer clone, either being induced or non-induced with cumate. More specifically, CHO cell metabolism in this clone was characterized by an efficient utilization of glucose and a high pyruvate dehydrogenase flux. Moreover, the high-producer clone shows a high rate of anaplerosis from pyruvate to oxaloacetate, through pyruvate carboxylase and from glutamate to α-ketoglutarate, through glutamate dehydrogenase, and a reduced rate of cataplerosis from malate to pyruvate, through malic enzyme. Indeed, the increase of flux through pyruvate carboxylase was not driven by an increased anabolic demand. It is in fact linked to an increase of the TCA cycle global flux, which allows better regulation of higher redox and more efficient metabolic states. To the best of our knowledge, this is the first time a dynamic in silico platform is proposed to analyze and compare the metabolomic behavior of different CHO clones.

Indexed as

AnimalsAntibodies, MonoclonalCHO CellsCitric Acid CycleCricetulusKetoglutaric AcidsMetabolomicsModels, TheoreticalPyruvate DecarboxylasePyruvic AcidAntibodies, MonoclonalKetoglutaric AcidsPyruvate DecarboxylasePyruvic Acid

Identifiers

PMID24632968
PMCPMC3954614
OpenAlexW2001064853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.